Comparing newer and standard immunochemotherapy for relapsed high-grade B-cell lymphoma
Compares newer and standard immune treatments in adults with returned aggressive B-cell lymphoma.
Key facts
- Who runs it
- Sung-Soo Park
- Where
- Seoul, South KoreaSee the 2 sites
- Trial code
- Registry title
- Immunotherapy in Lymphoma
- Status
- Recruiting
- People taking part
- 72 people, planned
- Started
- 26 Jun 2024
- Planned end
- 31 Dec 2025
- Type of study
- Observational, 2 groups
- Treatments tested
- CAR-T Therapy
- Bispecific antibody
- Antibody-Drug Conjugate
- Monoclonal antibody
- Proteasome Inhibitor
- IMiD treatment
- Record updated
- 28 January 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with relapsed or refractory aggressive B-cell lymphoma who have already had immunochemotherapy. It compares newer and classical immunochemotherapy.
- Age
- 19 to 74 years
- Sex
- All sexes can join.
- Disease stage
- Relapsed or refractory diffuse large B cell lymphoma, primary mediastinal large B cell lymphoma, high grade B cell lymphoma, or Burkitt lymphoma, diagnosed after January 2015.
- Earlier treatment
- Must have received immunochemotherapy for relapsed or refractory lymphoma.
Main reasons for not taking part
- Lymphoma that has progressed to acute leukemia
- A solid tumor that developed during treatment
- Active infection, such as acute pneumonia, viral infection, active hepatitis B or active pulmonary tuberculosis
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Adults aged 19 to 74 years
- Diagnosed with any of the following after January 2015: diffuse large B cell lymphoma, primary mediastinal large B cell lymphoma, high grade B cell lymphoma, or Burkitt lymphoma
- Patients who have received immunochemotherapy as treatment for relapsed/refractory lymphoma
Who cannot take part
- Patients with active infectious status (acute pneumonia, viral infection, active hepatitis B state, or active pulmonary tuberculosis etc.)
- Patients who have progressed to acute leukemia
- Patients who developed solid tumor during treatment
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 19 and 74 years old?
Where in South Korea
- Seoul St. Mary HospitalSeoul, South KoreaContact: Sung-Soo Park, MD. PhD.Taking people
- Yeoido St. Mary HospitalSeoul, South KoreaContact: Young-Woo Jeon, MD. PhD.Taking people
About the trial
What the trial wants to find out
The goal of this observational study is to compare the efficacy of advanced immunochemotherapy and classical immunochemotherapy in relapsed/refractory high grade B cell lymophoma patients. The main question it aims to answer is:
Read full original descriptionShow less
Does advanced immunochemotherapy, including CAR-T therapy, bispecific antibody, and antibody-drug conjugate offer superior survival outcomes than when treated with classical immunochemotherapy, such as proteasome inhibitors, immune modulatory drugs, and monoclonal antibodies?
Researchers will compare patients receiving advanced immunochemotherapy with those receiving classical immunochemotherapy to determine if advanced therapies result in better survival outcomes.
Laboratory findings and electronic medical records (EMR) from participants will be used to assess survival outcomes and treatment-related safety profiles.
The 2 groups in the trial
- Advanced immunochemotherapy
Relapsed/refractory high grade B cell lymphoma patients treated with either chimeric antigen receptor T cell therapy, bispecific antibody, or antibody-drug conjugate
Treatment: CAR-T Therapy, Bispecific antibody, and Antibody-Drug Conjugate
- Classical Immunochemotherapy
Relapsed/refractory high grade B cell lymphoma patients treated with either proteasome inhibitor, immune modulatory drug, or monoclonal antibody.
Treatment: Monoclonal antibody, Proteasome Inhibitor, and IMiD treatment
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Risk Factor Analysis Study for the Efficacy Comparison Between Advanced Immunochemotherapy and Classical Immunochemotherapy: a Prospective Study for Relapsed/Refractory Lymphoma Patients
- Plain-language title
- Comparing newer and standard immunochemotherapy for relapsed high-grade B-cell lymphomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06796517, who can take part
- Record updated
- 28 January 2025